Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.

NCT00761774 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00761774
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00761774 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.
Lead sponsor
UCB Pharma
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2008
Completion date
March 31, 2017
Enrollment
108 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy